Developer docs
API playgroundTry for free, no card

Search company profiles

Inventprise

Full company profile

uuid0002ahb

Namestring
Inventprise
Legal namestring
Inventprise, LLC
Websiteurl
inventprise.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Inventprise is a clinical-stage biotechnology company founded in 2012 by Dr. Subhash Kapre and headquartered in Redmond, Washington, developing conjugate and other vaccines for infectious diseases with disproportionate burden in low- and middle-income countries. Its core platform is a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology that enables high-valent vaccines (up to 25 serotypes) with reduced carrier suppression and broader serotype coverage than existing 10-20 valent pneumococcal conjugate vaccines. The lead candidate, IVT PCV-25, is in Phase 2 clinical evaluation, with a hexavalent Group B Streptococcus vaccine (IVT GBS-06) in Phase 1/2 and earlier-stage candidates targeting Shigella, Klebsiella, RSV (mRNA), COVID-19, and a dissolvable microneedle patch (D-MAP) delivery format.

The company operates over 100,000 square feet of manufacturing infrastructure, including a 70,000 sq ft highly automated cGMP facility in Woodinville, WA capable of producing tens of millions of doses annually, and offers contract manufacturing services to third parties. Its go-to-market motion is sales-led, targeting WHO prequalification and global health procurement channels (UNICEF, PAHO) with a stated commitment to LMIC-first launch at affordable pricing. The economic model is currently pre-revenue on products; the company is sustained by cumulative Bill & Melinda Gates Foundation program-related investment exceeding $100 million, with up to $90 million announced in November 2021 (first $30M tranche received April 2022). A November 2025 layoff of 76 employees reduced headcount to approximately 200 amid an ongoing clinical and infrastructure build-out.

Short descriptiontext

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate and mRNA vaccines for infectious diseases prevalent in low- and middle-income countries, using a proprietary Hz-PEG-Hydrazide linker platform and 100,000+ sq ft of automated cGMP manufacturing capacity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedmond, United States
HQ citystring
Redmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
conjugate vaccines, pneumococcal vaccines, vaccine manufacturing, bacterial vaccines, mRNA vaccines
Industry4 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine Product Sales
TypeOne Time License
Description

Inventprise is a clinical-stage vaccine invention company that will generate revenue through sales of its vaccine candidates once approved and commercialized. The company has committed to making IVT PCV-25 available at affordable prices to low- and middle-income countries through WHO prequalification and global health procurement channels (UNICEF, PAHO). Additional supply will be available for global demand outside LMICs.

inventprise.com
2Contract Manufacturing Services
TypeProfessional Services
Description

Inventprise offers contract manufacturing services in biologics from process-to-end user, including process development, optimization, analytical services, and manufacturing from early clinical trials through commercialization. Services leverage expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

inventprise.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate vaccines against infectious diseases with significant global health burden, using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform. Its pipeline includes IVT PCV-25 (25-valent pneumococcal conjugate vaccine), IVT GBS-06 (hexavalent Group B Streptococcal vaccine), Shigella and Klebsiella vaccine candidates, an mRNA RSV vaccine, and a dissolvable microneedle array patch (D-MAP) delivery technology. The company also operates over 100,000 square feet of cGMP manufacturing facilities in Washington State and offers contract manufacturing services for biologics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IVT PCV-25 targets 25 serotypes vs 10-15 in current licensed vaccines, addressing remaining pneumococcal disease burden
+3 more records
Product overview1 text field

Inventprise is a clinical-stage vaccine invention company with a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology platform. The company's product portfolio centers on high-valent conjugate vaccines targeting infectious diseases with significant global health burden. Core products include: IVT PCV-25 (25-valent pneumococcal conjugate vaccine in Phase 2 for adults and infants), IVT GBS-06 (hexavalent Group B Streptococcal vaccine for maternal immunization in Phase 1/2), IVT Shigella-04 (quadrivalent Shigella vaccine), IVT Klebsiella vaccine, and an mRNA RSV vaccine using Quantoom Biosciences' Ntensify technology. The company also develops a dissolvable microneedle array patch (IVT D-MAP) and has published preclinical results on a COVID-19 conjugate vaccine. Manufacturing capabilities span over 100,000 sq ft across Redmond and Woodinville, WA facilities with contract services offered to partners. The company was founded in 2012 by Dr. Subhash Kapre and is headquartered in Redmond, Washington with a European office in Switzerland.

Product and service8 records
1IVT PCV-25
CategoryCore product
Description

25-valent pneumococcal conjugate vaccine for pediatric and adult populations, leveraging Inventprise's proprietary Hz-PEG-Hz linker conjugation platform to provide broader coverage (25 serotypes) against pneumococcal disease than existing vaccines covering 10-20 serotypes. Currently in Phase 2 clinical trials.

2IVT GBS-06
CategoryCore product
Description

Hexavalent Group B Streptococcal (GBS) conjugate vaccine candidate for maternal immunization, covering serotypes Ia, Ib, II, III, V, and VII, representing approximately 99% of GBS serotypes causing stillbirth and 98-99% of early/late onset disease. Designed to prevent GBS disease in neonates and young infants.

3IVT Shigella-04
CategoryCore product
Description

Quadrivalent Shigella conjugate vaccine candidate designed to reduce morbidity and mortality from shigellosis, which causes 80 million cases and 700,000 deaths annually, mostly in children under 5 in low- and middle-income countries. Supported by funding from the Bill & Melinda Gates Foundation.

4IVT Klebsiella
CategoryCore product
Description

Klebsiella vaccine candidate leveraging Inventprise's proprietary Hz-PEG-Hz conjugation platform, designed to reduce neonatal mortality from bacterial infections caused by Klebsiella pneumoniae and decrease emergence of antimicrobial resistance.

5mRNA RSV Vaccine
CategoryCore product
Description

Respiratory Syncytial Virus (RSV) mRNA vaccine candidate developed using Quantoom Biosciences' Ntensify midi system for mRNA production. Part of Inventprise's mRNA vaccine platform for rapid response to infectious diseases. Supported by Gates Foundation funding.

6COVID-19 Conjugate Vaccine
CategoryCore product
Description

Bivalent SARS-CoV-2 conjugate vaccine using proprietary Hz-PEG-Hz linker protein conjugation technology with detoxified diphtheria-derived carrier protein (rCRM197). Demonstrated broad neutralizing antibody responses across multiple SARS-CoV-2 variants in preclinical studies published in Vaccine Journal.

7IVT D-MAP
CategoryCore product
Description

Dissolvable Microneedle Array Patch (D-MAP) for vaccine delivery. Pain-free, easy to use, small in size (1 cm²) with potential for thermostability and elimination of cold-chain requirements. Multiple antigens can be included on one patch.

8Contract Manufacturing Services
CategoryService
Description

Comprehensive contract services including process development, clinical and commercial manufacturing, quality and regulatory programming, and automation design for biologics. Leverages subject matter expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-15
Description

Inventprise selected Quantoom Biosciences' Ntensify midi system as core technology for its mRNA vaccine platform. The system enables production of high-yield, low-contaminant GMP-grade mRNA with scalable and automated solution from Phase I to commercial. As proof of concept, Inventprise is developing an RSV vaccine using this technology, supported by Gates Foundation funding.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Wits VIDA in Johannesburg, South Africa is conducting the Phase 1/2 clinical study of Inventprise's hexavalent GBS vaccine candidate (IVT GBS-06). Prof. Shabir Madhi presented interim results at ISSAD 2026 in Nairobi, Kenya.

3Canadian Immunization Research Network (CIRN)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-10
Description

Collaboration with CIRN for Phase 1/2 clinical evaluation of IVT PCV-25. Study conducted at Canadian Center for Vaccinology (Halifax), Vaccine Evaluation Center (British Columbia), Colchester Research Group (Nova Scotia), and Centre de recherche Saint-Louis (Quebec).

inventprise.com
4PATH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

PATH (international nonprofit global health organization) collaborates with Inventprise on vaccine development, regulatory submissions (Health Canada), and technical support for IVT PCV-25. PATH has featured Inventprise's expanded-coverage pneumococcal vaccine in their publications.

inventprise.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Merck's Prevnar 20 (20-valent PCV) is the established market leader in pneumococcal conjugate vaccines and is the comparator used in Inventprise's PCV-25 Phase 2 trials. Directly comparable in target indication and vaccine technology category, but at vastly larger scale with established commercial infrastructure.

2Biological E
TypeDirect peer
Description

Biological E is an Indian vaccine manufacturer developing WHO-prequalified conjugate vaccines including PCVs targeting LMICs. Inventprise's VP of Manufacturing previously served as Associate VP-R&D at Biological E. Directly comparable as a high-volume, low-cost PCV competitor for global health procurement.

TypeBroad incumbent
Description

GSK has a competing PCV franchise (Synflorix) and acquired Affinivax for next-generation MAPS (Multiple Antigen Presenting System) vaccine technology. Comparable as a global vaccine manufacturer with overlapping pipeline in pneumococcal and other infectious disease vaccines.

TypeBroad incumbent
Description

Pfizer developed the original Prevnar franchise and is developing higher-valent PCVs. As a top-2 incumbent in the pneumococcal vaccine market, Pfizer is the most direct competitive threat to Inventprise's PCV-25 positioning.

TypeDirect peer
Description

Bharat Biotech is an Indian vaccine manufacturer with WHO-prequalified vaccines and active PCV development. Comparable as an emerging global vaccine developer targeting similar LMIC markets and infectious disease indications with cost-competitive manufacturing.

TypeBroad incumbent
Description

Sanofi is a top-5 global vaccine manufacturer with broad portfolio including pediatric and adult vaccines. Comparable as a large incumbent with established global distribution and competing in similar infectious disease indications targeted by Inventprise's pipeline.

TypeDirect peer
Description

Novavax is a clinical-to-commercial-stage vaccine developer using novel protein nanoparticle technology. Comparable as a non-incumbent vaccine developer focused on infectious diseases, with similar capital-intensive path to commercialization.

TypeDirect peer
Description

Inventprise founder Subhash Kapre previously led conjugate vaccine development at Serum Institute for 40 years. Serum Institute produces Pneumosil (10-valent PCV) and other conjugate vaccines at massive scale targeting LMICs, making it the most operationally and commercially comparable peer, particularly in WHO prequalification/LMIC tender dynamics.

TypeEmerging player
Description

VBI Vaccines is a clinical-stage vaccine developer with proprietary eVLP platform technology targeting infectious diseases including CMV and hepatitis B. Comparable as a small-cap vaccine developer with proprietary platform technology targeting similar disease areas, though at different stages.

TypeBroad incumbent
Description

Moderna is the leading mRNA vaccine platform company. Inventprise's May 2025 selection of Quantoom's Ntensify system positions its mRNA platform in direct competition for pandemic preparedness contracts where speed-to-clinic is critical.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inventprise

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate and mRNA vaccines for infectious diseases prevalent in low- and middle-income countries, using a proprietary Hz-PEG-Hydrazide linker platform and 100,000+ sq ft of automated cGMP manufacturing capacity.

What Inventprise does

Inventprise is a clinical-stage biotechnology company founded in 2012 by Dr. Subhash Kapre and headquartered in Redmond, Washington, developing conjugate and other vaccines for infectious diseases with disproportionate burden in low- and middle-income countries. Its core platform is a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology that enables high-valent vaccines (up to 25 serotypes) with reduced carrier suppression and broader serotype coverage than existing 10-20 valent pneumococcal conjugate vaccines. The lead candidate, IVT PCV-25, is in Phase 2 clinical evaluation, with a hexavalent Group B Streptococcus vaccine (IVT GBS-06) in Phase 1/2 and earlier-stage candidates targeting Shigella, Klebsiella, RSV (mRNA), COVID-19, and a dissolvable microneedle patch (D-MAP) delivery format.

The company operates over 100,000 square feet of manufacturing infrastructure, including a 70,000 sq ft highly automated cGMP facility in Woodinville, WA capable of producing tens of millions of doses annually, and offers contract manufacturing services to third parties. Its go-to-market motion is sales-led, targeting WHO prequalification and global health procurement channels (UNICEF, PAHO) with a stated commitment to LMIC-first launch at affordable pricing. The economic model is currently pre-revenue on products; the company is sustained by cumulative Bill & Melinda Gates Foundation program-related investment exceeding $100 million, with up to $90 million announced in November 2021 (first $30M tranche received April 2022). A November 2025 layoff of 76 employees reduced headcount to approximately 200 amid an ongoing clinical and infrastructure build-out.

Inventprise firmographics

Firmographics
Name
Inventprise
Legal name
Inventprise, LLC
Website
https://inventprise.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Inventprise is a clinical-stage biotechnology company developing high-valent conjugate and mRNA vaccines for infectious diseases prevalent in low- and middle-income countries, using a proprietary Hz-PEG-Hydrazide linker platform and 100,000+ sq ft of automated cGMP manufacturing capacity.
Ownership category
akta.pro rank

Inventprise industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Conjugate vaccines
  • Pneumococcal vaccines
  • Vaccine manufacturing
  • Bacterial vaccines
  • MRNA vaccines

Where Inventprise is headquartered

Location

Headquarters

HQ city
Redmond
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Inventprise business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Vaccine Product Sales: Inventprise is a clinical-stage vaccine invention company that will generate revenue through sales of its vaccine candidates once approved and commercialized. The company has committed to making IVT PCV-25 available at affordable prices to low- and middle-income countries through WHO prequalification and global health procurement channels (UNICEF, PAHO). Additional supply will be available for global demand outside LMICs.
  2. Contract Manufacturing Services: Inventprise offers contract manufacturing services in biologics from process-to-end user, including process development, optimization, analytical services, and manufacturing from early clinical trials through commercialization. Services leverage expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Inventprise product offering

Product offering

Core offering

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate vaccines against infectious diseases with significant global health burden, using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform. Its pipeline includes IVT PCV-25 (25-valent pneumococcal conjugate vaccine), IVT GBS-06 (hexavalent Group B Streptococcal vaccine), Shigella and Klebsiella vaccine candidates, an mRNA RSV vaccine, and a dissolvable microneedle array patch (D-MAP) delivery technology. The company also operates over 100,000 square feet of cGMP manufacturing facilities in Washington State and offers contract manufacturing services for biologics.

Product overview

Inventprise is a clinical-stage vaccine invention company with a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology platform. The company's product portfolio centers on high-valent conjugate vaccines targeting infectious diseases with significant global health burden. Core products include: IVT PCV-25 (25-valent pneumococcal conjugate vaccine in Phase 2 for adults and infants), IVT GBS-06 (hexavalent Group B Streptococcal vaccine for maternal immunization in Phase 1/2), IVT Shigella-04 (quadrivalent Shigella vaccine), IVT Klebsiella vaccine, and an mRNA RSV vaccine using Quantoom Biosciences' Ntensify technology. The company also develops a dissolvable microneedle array patch (IVT D-MAP) and has published preclinical results on a COVID-19 conjugate vaccine. Manufacturing capabilities span over 100,000 sq ft across Redmond and Woodinville, WA facilities with contract services offered to partners. The company was founded in 2012 by Dr. Subhash Kapre and is headquartered in Redmond, Washington with a European office in Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

  • IVT PCV-25 25-valent pneumococcal conjugate vaccine for pediatric and adult populations, leveraging Inventprise's proprietary Hz-PEG-Hz linker conjugation platform to provide broader coverage (25 serotypes) against pneumococcal disease than existing vaccines covering 10-20 serotypes. Currently in Phase 2 clinical trials.
  • IVT GBS-06 Hexavalent Group B Streptococcal (GBS) conjugate vaccine candidate for maternal immunization, covering serotypes Ia, Ib, II, III, V, and VII, representing approximately 99% of GBS serotypes causing stillbirth and 98-99% of early/late onset disease. Designed to prevent GBS disease in neonates and young infants.
  • IVT Shigella-04 Quadrivalent Shigella conjugate vaccine candidate designed to reduce morbidity and mortality from shigellosis, which causes 80 million cases and 700,000 deaths annually, mostly in children under 5 in low- and middle-income countries. Supported by funding from the Bill & Melinda Gates Foundation.
  • IVT Klebsiella Klebsiella vaccine candidate leveraging Inventprise's proprietary Hz-PEG-Hz conjugation platform, designed to reduce neonatal mortality from bacterial infections caused by Klebsiella pneumoniae and decrease emergence of antimicrobial resistance.
  • mRNA RSV Vaccine Respiratory Syncytial Virus (RSV) mRNA vaccine candidate developed using Quantoom Biosciences' Ntensify midi system for mRNA production. Part of Inventprise's mRNA vaccine platform for rapid response to infectious diseases. Supported by Gates Foundation funding.
  • COVID-19 Conjugate Vaccine Bivalent SARS-CoV-2 conjugate vaccine using proprietary Hz-PEG-Hz linker protein conjugation technology with detoxified diphtheria-derived carrier protein (rCRM197). Demonstrated broad neutralizing antibody responses across multiple SARS-CoV-2 variants in preclinical studies published in Vaccine Journal.
  • IVT D-MAP Dissolvable Microneedle Array Patch (D-MAP) for vaccine delivery. Pain-free, easy to use, small in size (1 cm²) with potential for thermostability and elimination of cold-chain requirements. Multiple antigens can be included on one patch.
  • Contract Manufacturing Services Comprehensive contract services including process development, clinical and commercial manufacturing, quality and regulatory programming, and automation design for biologics. Leverages subject matter expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

Quantifiable outcome

  • IVT PCV-25 targets 25 serotypes vs 10-15 in current licensed vaccines, addressing remaining pneumococcal disease burden
  • +3 more outcomes

Companies that use Inventprise

Customer profile

Segments3 records

Ideal customer profiles2 records

Inventprise technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Inventprise partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Quantoom BiosciencescoreTechnology or Integration · 15 May 2025Inventprise selected Quantoom Biosciences' Ntensify midi system as core technology for its mRNA vaccine platform. The system enables production of high-yield, low-contaminant GMP-grade mRNA with scalable and automated solution from Phase I to commercial. As proof of concept, Inventprise is developing an RSV vaccine using this technology, supported by Gates Foundation funding.
  • Wits Vaccines & Infectious Diseases Analytics (VIDA) Research UnitminorStrategic or Co-development Partner · 12 November 2024Wits VIDA in Johannesburg, South Africa is conducting the Phase 1/2 clinical study of Inventprise's hexavalent GBS vaccine candidate (IVT GBS-06). Prof. Shabir Madhi presented interim results at ISSAD 2026 in Nairobi, Kenya.
  • Canadian Immunization Research Network (CIRN)minorStrategic or Co-development Partner · 10 November 2022Collaboration with CIRN for Phase 1/2 clinical evaluation of IVT PCV-25. Study conducted at Canadian Center for Vaccinology (Halifax), Vaccine Evaluation Center (British Columbia), Colchester Research Group (Nova Scotia), and Centre de recherche Saint-Louis (Quebec).
  • PATHcoreStrategic or Co-development PartnerPATH (international nonprofit global health organization) collaborates with Inventprise on vaccine development, regulatory submissions (Health Canada), and technical support for IVT PCV-25. PATH has featured Inventprise's expanded-coverage pneumococcal vaccine in their publications.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Inventprise competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Merck's Prevnar 20 (20-valent PCV) is the established market leader in pneumococcal conjugate vaccines and is the comparator used in Inventprise's PCV-25 Phase 2 trials. Directly comparable in target indication and vaccine technology category, but at vastly larger scale with established commercial infrastructure.
  • GSK: GSK has a competing PCV franchise (Synflorix) and acquired Affinivax for next-generation MAPS (Multiple Antigen Presenting System) vaccine technology. Comparable as a global vaccine manufacturer with overlapping pipeline in pneumococcal and other infectious disease vaccines.
  • Pfizer: Pfizer developed the original Prevnar franchise and is developing higher-valent PCVs. As a top-2 incumbent in the pneumococcal vaccine market, Pfizer is the most direct competitive threat to Inventprise's PCV-25 positioning.
  • Sanofi: Sanofi is a top-5 global vaccine manufacturer with broad portfolio including pediatric and adult vaccines. Comparable as a large incumbent with established global distribution and competing in similar infectious disease indications targeted by Inventprise's pipeline.
  • Moderna: Moderna is the leading mRNA vaccine platform company. Inventprise's May 2025 selection of Quantoom's Ntensify system positions its mRNA platform in direct competition for pandemic preparedness contracts where speed-to-clinic is critical.

Direct peers

  • Biological E: Biological E is an Indian vaccine manufacturer developing WHO-prequalified conjugate vaccines including PCVs targeting LMICs. Inventprise's VP of Manufacturing previously served as Associate VP-R&D at Biological E. Directly comparable as a high-volume, low-cost PCV competitor for global health procurement.
  • Bharat Biotech: Bharat Biotech is an Indian vaccine manufacturer with WHO-prequalified vaccines and active PCV development. Comparable as an emerging global vaccine developer targeting similar LMIC markets and infectious disease indications with cost-competitive manufacturing.
  • Novavax: Novavax is a clinical-to-commercial-stage vaccine developer using novel protein nanoparticle technology. Comparable as a non-incumbent vaccine developer focused on infectious diseases, with similar capital-intensive path to commercialization.
  • Serum Institute of India: Inventprise founder Subhash Kapre previously led conjugate vaccine development at Serum Institute for 40 years. Serum Institute produces Pneumosil (10-valent PCV) and other conjugate vaccines at massive scale targeting LMICs, making it the most operationally and commercially comparable peer, particularly in WHO prequalification/LMIC tender dynamics.

Emerging players

  • VBI Vaccines: VBI Vaccines is a clinical-stage vaccine developer with proprietary eVLP platform technology targeting infectious diseases including CMV and hepatitis B. Comparable as a small-cap vaccine developer with proprietary platform technology targeting similar disease areas, though at different stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Inventprise social profiles

Digital presence

Inventprise financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inventprise leadership team

Management profile

Number of profiles

Profiles9 records

Inventprise funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inventprise M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inventprise

What does Inventprise do?

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate vaccines against infectious diseases with significant global health burden, using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform. Its pipeline includes IVT PCV-25 (25-valent pneumococcal conjugate vaccine), IVT GBS-06 (hexavalent Group B Streptococcal vaccine), Shigella and Klebsiella vaccine candidates, an mRNA RSV vaccine, and a dissolvable microneedle array patch (D-MAP) delivery technology. The company also operates over 100,000 square feet of cGMP manufacturing facilities in Washington State and offers contract manufacturing services for biologics.

Is Inventprise a public or private company?

Inventprise is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inventprise founded?

Inventprise was founded in 2012. It employs 51 to 100 people.

Where is Inventprise based?

Inventprise is headquartered in Redmond, United States, in the North America region.

How does Inventprise make money?

Two revenue lines are on record. Vaccine Product Sales are the primary driver. The others are contract Manufacturing Services.

Who are Inventprise's main competitors?

Broad incumbents on record are Merck & Co., GSK, Pfizer, Sanofi and Moderna. Direct peers are Biological E, Bharat Biotech, Novavax and Serum Institute of India. VBI Vaccines is listed as an emerging player.

Does Inventprise have an API?

No public API is recorded for Inventprise.

What industry is Inventprise in?

Inventprise's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MDPIAnalytical Characterization of Pneumococcal Vaccine Conjugates Using SEC-MALS TechniqueResearchers at Inventprise, Inc. demonstrated the applicability of SEC-MALS (size-exclusion chromatography-multi-angle light scattering) technique for analytical characterization of pneumococcal conjugate vaccines, analyzing seven serotypes conjugated to rCRM197 carrier protein. The study achieved greater than 90% accuracy and less than 2% RSD repeatability in molar mass measurements, while also enabling compositional analysis and monitoring of conjugation reaction kinetics. By adjusting process conditions based on SEC-MALS monitoring, the team obtained conjugates with desired molar mass ranges suitable for vaccine development.MynorthwestRedmond-based vaccine company laying off 76 employeesRedmond-based vaccine developer Inventprise plans to lay off 76 employees, with the first cuts scheduled for December 31 and additional reductions in early 2026. The company attributes the workforce reduction to organizational changes aimed at aligning operations with a reduced operating budget and ensuring long-term sustainability.GeekWireFiling: Seattle-area vaccine company Inventprise laying off 76 employeesInventprise, a Redmond, Washington-based biotechnology company developing vaccines for infectious diseases, is laying off 76 workers across its Redmond and Woodinville facilities and among remote employees, with separations effective December 31. The layoffs affect approximately 40% of the company's nearly 200 employees and span manufacturing, quality control, research and development, and technical roles. The company, which focuses on addressing global health challenges in low- and middle-income countries, has its lead candidate IVT-PCV-25, a pneumococcal conjugate vaccine, in Phase 2 trials.GlobeNewswireInventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine JournalInventprise published a preclinical study in Vaccine Journal showing its bivalent SARS-CoV-2 conjugate vaccine elicited broad neutralizing antibodies and T-cell immunity. The 18-month study suggests potential for longer-lasting protection, possibly reducing booster needs. The company is seeking funding and partnerships to advance the findings.Clinical Trials ArenaInventprise completes dosing in Phase II pneumococcal vaccine studyInventprise has completed vaccine administration for a Phase II study evaluating three dose levels of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in 220 young adults across four sites in Canada. The trial results are intended to support the planning of subsequent Phase II studies in infants and older adults scheduled for later in 2024. This development positions Inventprise's candidate against existing market leaders like Pfizer’s Prevnar20 and MSD’s investigational V116.BioSpaceNew Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical EvaluationBiotechnology company Inventprise has initiated a Phase 1/2 clinical study for its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Halifax, Canada. The study, conducted in collaboration with PATH and the Canadian Immunization Research Network, aims to evaluate the safety and immune response of the expanded-coverage vaccine in adults, children, and infants. This development is supported by funding from the Bill & Melinda Gates Foundation and seeks to address serotypes not covered by current vaccines.GeekWireBill Gates helps open new vaccine manufacturing facility in Seattle areaBill Gates attended the ribbon-cutting ceremony for Inventprise's new 70,000-square-foot vaccine manufacturing facility in Woodinville, Washington. The plant, supported by over $190 million in funding from the Bill & Melinda Gates Foundation, is designed to produce low-cost vaccines against pneumococcal disease and other illnesses using automated technology. If upcoming clinical trials succeed, the facility will be positioned to manufacture tens of millions of doses annually for both commercial and developing markets.trib.alGates Foundation commits up to $90M for Inventprise pneumococcal vax trialsThe Bill & Melinda Gates Foundation has committed up to $90 million to support Inventprise in conducting clinical trials for its pneumococcal vaccine candidate, IVT-25. This funding will cover Phase 1 and Phase 2 testing, aiming to develop a vaccine that protects against 25 strains of bacteria, surpassing the coverage of current market offerings from Pfizer and Merck. The initiative targets affordable protection for vulnerable children in low- and middle-income countries.BioSpaceGates Foundation Pours $90 Million into Promising New Pneumococcal VaccineThe Bill & Melinda Gates Foundation has invested $90 million in Seattle-area biotech Inventprise, which is developing a pneumococcal conjugate vaccine covering more than 90 known Streptococcus pneumoniae strains. Inventprise's proprietary linker molecule allows more vaccine components without losing potency, and the Gates funding should move IVT-25 through Phase I and II testing starting next year.